Engineering Pasteurella Multocida Heparosan Synthase 2 (Pmhs2) For Efficient Synthesis Of Heparosan Heparin And Heparan Sulfate Oligosaccharides

Abstract

Researchers at the University of California, Davis have developed improved variants of a Heparosan synthase supporting efficient synthesis of heparosan, heparin, and heparan sulfate analogs.

Full Description

Researchers at the University of California Davis have developed a technology that employs engineered variants of Pasteurella multocida heparosan synthase 2 (PmHS2) for efficient synthesis of heparosan, heparin, and heparan sulfate oligosaccharides/polysaccharides and analogs. These variants have enhanced expression levels, improved thermal stability, and reduced reverse glycosylation activity, thereby increasing the synthetic efficiency and overall yields.

Applications

• Biomedical research for understanding the role of heparan sulfate in cellular processes 
• Pharmaceutical industry for the manufacture of anticoagulants such as heparin 
• Development of new therapeutic drugs and interventions

Features/Benefits

• Increased expression levels 
• Improved heat resistance 
• Reduced reverse glycosylation activity 
• Efficient synthesis of heparosan, heparin, and heparan sulfate analogs 
• Addresses challenges in synthesizing heparan sulfate-like oligosaccharides and polysaccharides 
• Solves low synthetic efficiency of existing methods 
• Addresses difficulty of obtaining homogeneous, structurally defined heparan sulfate

Patent Status